Fig. 3.
Ratio (%) of patients studied presenting symptoms of bronchial hyperreactivity (BHR) or on treatment with oral corticosteroids (OCS) at baseline and after 4 and 12 months of TLA use.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.